Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport

Oncotarget

Volumn 7, Issue 32, 2016, Pages 51435-51449

  Velez, Juliana ^a,b   Pan, Rongqing ^e   Lee, Jason T C ^f   Enciso, Leonardo ^b   Suarez, Marta ^b   Duque, Jorge Eduardo ^c   Jaramillo, Daniel ^a   Lopez, Catalina ^d   Morales, Ludis ^a   Bornmann, William ^e   Konopleva, Marina ^e   Krystal, Gerald ^f   Andreeff, Michael ^e   Samudio, Ismael ^a,b,g  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Programa de Investigacion e Innovacion en Leucemia Aguda y Cronica   (Colombia)

^c Centro Oncológico de Antioquia   (Colombia)

^d UNIVERSIDAD DE CALDAS   (Colombia)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Centre for Drug Research and Development   (Canada)

Author keywords

ABT 737; Leukemia; Metformin; Mitochondria; Phenformin

Indexed keywords

GLUTATHIONE; METFORMIN; PHENFORMIN; PROTEIN BAK; ROTENONE; SUPEROXIDE; TRIACYLGLYCEROL; VENETOCLAX; ABT-737; BIGUANIDE DERIVATIVE; BIPHENYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ELECTRON TRANSPORT; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE PERMEABILITY; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; OLIGOMERIZATION; SIGNAL TRANSDUCTION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; METABOLISM; MITOCHONDRION; TUMOR CELL LINE; U-937 CELL LINE;

APOPTOSIS; BIGUANIDES; BIPHENYL COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ELECTRON TRANSPORT; HUMANS; METFORMIN; MITOCHONDRIA; NITROPHENOLS; PHENFORMIN; PIPERAZINES; ROTENONE; SULFONAMIDES; U937 CELLS;

EID: 84982307711     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9843     Document Type: Article

References (45)

1. Ofran Y and Rowe JM. Treatment for relapsed acute myeloid leukemia: what is new? Curr Opin Hematol. 2012; 19:89-94.
2. Narayanan S and Shami PJ. Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2012; 81:94-102.
3. Konopleva M and Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets. 2007; 8:685-701.
4. Tabe Y, Konopleva M, Igari J and Andreeff M. Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex. Rinsho Byori. 2004; 52:642-648.
5. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25:1315-1321.
6. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K and Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer research. 2008; 68:5198-5205.
7. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H and Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. The Journal of clinical investigation. 2010; 120:142-156.
8. Samudio I, Fiegl M and Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer research. 2009; 69:2163-2166.
9. Starr P. Venetoclax Shows Strong Activity in CLL. Am Health Drug Benefits. 2016; 9:21.
10. Venetoclax Approved for CLL. Cancer Discov. 2016.
11. Dowling RJ, Niraula S, Stambolic V and Goodwin PJ. Metformin in cancer: translational challenges. Journal of molecular endocrinology. 2012; 48:R31-43.
12. Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF. Metformin and cancer therapy. Curr Opin Oncol. 2012; 24:103-108.
13. Xie Z, Dong Y, Scholz R, Neumann D and Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008; 117:952-962.
14. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of clinical investigation. 2010; 120:2355-2369.
15. Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA and Chen J. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A. 2008; 105:8286-8291.
16. Owen MR, Doran E and Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000; 348:607-614.
17. Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A and McCubrey JA. Targeting the liver kinase B1/AMPactivated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Ther Targets. 2012; 16:729-742.
18. Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell cycle. 2009; 8:88-96.
19. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC and Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11:390-401.
20. Nair V, Pathi S, Jutooru I, Sreevalsan S, Basha R, Abdelrahim M, Samudio I and Safe S. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis. 2013; 34:2870-2879.
21. Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, McPherson C, Warnick RE, Kendler A, Giri S, Poels J, Norga K, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A. 2014; 111:E435-444.
22. Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, Senegas I, Peyraud R, Peyriga L, Theodoro F, Dumon E, Martineau Y, Danet-Desnoyers G, Bono F, Rocher C, Levade T, et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia. 2013; 27:2129-2138.
23. Kohli R, Pan X, Malladi P, Wainwright MS and Whitington PF. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. The Journal of biological chemistry. 2007; 282:21327-21336.
24. Koppers AJ, Garg ML and Aitken RJ. Stimulation of mitochondrial reactive oxygen species production by unesterified, unsaturated fatty acids in defective human spermatozoa. Free Radic Biol Med. 2010; 48:112-119.
25. Corominas-Faja B, Quirantes-Pine R, Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A and Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012; 4:480-498. doi:10.18632/aging.100472.
26. Howard AN, Bridges KA, Meyn RE and Chandra J. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. Cancer Chemother Pharmacol. 2009; 65:41-54.
27. Welters HJ, Tadayyon M, Scarpello JH, Smith SA and Morgan NG. Mono-unsaturated fatty acids protect against beta-cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure. FEBS Lett. 2004; 560:103-108.
28. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P and Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond). 2007; 113:205-212.
29. Cabrero A, Merlos M, Laguna JC and Carrera MV. Downregulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res. 2003; 44:388-398.
30. Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, Konopleva M, Andreeff M, Lee MH and Yeung SC. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell cycle. 2012; 11:2314-2326.
31. Shimizu I, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Ito T, Zechner R, Komuro I, Kobayashi Y and Minamino T. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 2012; 15:51-64.
32. Garcia Fernandez MI, Ceccarelli D and Muscatello U. Use of the fluorescent dye 10-N-nonyl acridine orange in quantitative and location assays of cardiolipin: a study on different experimental models. Anal Biochem. 2004; 328:174-180.
33. Dai H, Ding H, Meng XW, Peterson KL, Schneider PA, Karp JE and Kaufmann SH. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev. 2015; 29:2140-2152.
34. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ and Cohen GM. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ. 2008; 15:820-830.
35. Gonzalvez F, Pariselli F, Jalmar O, Dupaigne P, Sureau F, Dellinger M, Hendrickson EA, Bernard S and Petit PX. Mechanistic issues of the interaction of the hairpin-forming domain of tBid with mitochondrial cardiolipin. PloS one. 2010; 5:e9342.
36. Sani MA, Dufourc EJ and Grobner G. How does the Baxalpha1 targeting sequence interact with mitochondrial membranes? The role of cardiolipin. Biochim Biophys Acta. 2009; 1788:623-631.
37. Landeta O, Landajuela A, Gil D, Taneva S, Di Primo C, Sot B, Valle M, Frolov VA and Basanez G. Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAK-driven membrane permeabilization process. The Journal of biological chemistry. 2011; 286:8213-8230.
38. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer cell. 2006; 10:375-388.
39. Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism. Blood. 2016.
40. Venetoclax Yields Strong Responses in CLL. Cancer Discov. 2016; 6:113-114.
41. Brower V. Venetoclax targets BCL2 in chronic lymphocytic leukaemia. Lancet Oncol. 2016; 17:e11.
42. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27:3297-3302.
43. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R, Ruschoff JH, Cathomas R and Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014; 66:468-474.
44. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN and Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013; 71:63-72.
45. Mitsuhashi A, Kiyokawa T, Sato Y and Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014; 120:2986-2995.